NEW YORK (dpa-AFX Broker) - Analysts Jefferies left its rating on Dermapharm at "Buy" with a price target of 65 euros after preliminary quarterly figures. Profitability was significantly higher than expected, wrote analyst Alexander Thiel in a first reaction available on Wednesday. He also praised the drugmaker's raised outlook for the year./edh/la
Original publication date: 08/16/2023 / 02:10 / ET
First disclosure of original study: 08/16/2023 / 02:10 / ET
-----------------------
dpa-AFX Broker - the Trader News from dpa-AFX
-----------------------